1Kenneth KW;Wang XN;Yu Ch W.Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin[J],2004(17).
2Sakoff J A;Ackland S P;Garget M.Protein phosphatase 2A,a novel and unexplored anticancer target,2002(07).
3William A D.Prodrug strategies in cancer therapy[J],2001(7/8).
4AbuKhader M;Heap J;Matteis D.Binding of the Anticancer Prodrug CB1954 to the Activating Enzyme NQO2 Revealed by the Crystal Structure of Their Complex[J],2005(24).
5Xie H J;Griskevicius L;Stahle L.Pharmacogenetics of cyclophosphamide in patients with hematological malignancies[J],2006(01).
6Hillemann A;Brandenburg B;Schmidt U.Protein transduction with bacterial cytosine deaminase fused to the TLM intercellular transport motif induces profound chemosensitivity to 5-fluorocytosine in human hepatoma cells[J],2005(03).
7Fu Y;Buryanovskyy L;Zhang Zh T.Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954[J],2005(01).
8Margarita F;Bianchet M A;Winski S.Structure-Based Development of Anticancer Drugs:Complexes of NAD(P)H:Quinone Oxidoreductase 1 with Chemotherapeutic Quinones[J],2001(08).
9Lee HH;Wilson WR;Ferry DM.A Hypoxia-Selective Antitumor Agents.13.Effects of Acridine Substitution on the Hypoxia-Selective Cytotoxicity and Metabolic Reduction of the Bisbioreductive Agent Nitracrine N-Oxide[J],1996(13).
10Cai T B;Lu D;Tang X Zh.New Glycosidase Activated Nitric Oxide Donors:Glycose and 3-Morphorlinosydnonimine Conjugates[J],2005(09).
5Ettmayer P, Amidon GL, Clement B, et al. Les- sons learned from marketed and investigational pro- drugs [J]. J Med Chem, 2004, 47(10): 2393- 2404.
6Beaumont K, Webster R, Gardner I, et al. Design of ester prodrugs to enhance oral absorption ofpoorly permeable compounds: challenges to the dis- covery scientists[J]. Curr Drug Metab, 2003, 4 (6) : 461-485.
7Wu KM. A new classification of prodrugs: regula- tory perspectives[J]. Pharmaceuticals, 2009, 2 (3):77-81.
8Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications[J].Nat Rev Drug Discov, 2008, 7(3) : 255-270.
9Testa B. Prodrug research: futile or fertile[J]. Bio- chem Pharmacol, 2004, 68(11): 2097-2106.
10Cundy KC, Sastry S, Luo W, et al. Clinical phar- macokinetics of XP13512, a novel transported pro- drug of Gabapentin [J]. J Clin Pharmacol, 2008, 48(12) : 1378-1388.
